Tag:
Bristol-Myers Squibb
Latest Headlines
Latest Headlines
Another one bites the dust: Plavix falls off patent today
Yet another milestone on pharma's journey away from the megablockbuster era: Plavix, the gold-standard clotbuster, goes off patent today.
Ex-BMS exec finishes book, and sentence, in conviction
A former Bristol-Myers Squibb executive has completed his sentence with a book on the Plavix scandal.
Cancer drug experts brace for ASCO abstract dump tonight
ASCO is releasing a mountain of data on cancer studies, and some of the biggest names in the business will be angling for star billing on some closely watched therapies.
Big-name pharmas peer at Amylin's books to prep for bids
The world's biggest drugmakers have lined up to take a look at Amylin's books as the U.S.-based company prepares to entertain a first round of bids.
Buzz: Big Pharma suitors line up for a look at Amylin's books
One of the cardinal rules involved in deal-making focuses on the need to get as many buyers to the negotiating table as possible. The next big rule: Make sure everyone knows who's interested in bidding.
Bristol turns to blockbuster pipeline as Plavix goes generic
With clot-buster Plavix facing generic competition, the company is banking on some more wins in its pipeline to replace revenue from declining sales of its top seller.
Bristol-Myers hits estimates for the quarter but still faces tough going
Facing a generic onslaught next month for its best-selling Plavix , Bristol-Myers Squibb managed to bring in earnings that at least met expectations.
Bristol-Myers Squibb confirms it's a target of bribery probe
Bristol-Myers Squibb has made it official. It is under federal investigation, potentially for foreign bribery.
BMS delivers sales, profit growth in Plavix's final quarter
All eyes are on new and forthcoming drugs as Bristol-Myers Squibb reports a 12% increase in first-quarter profits.
Amylin's up for bid. Who'll step in line?
Step right up, Big Pharma bidders. Amylin Pharmaceuticals is up for auction.
